Serum type III procollagen, procollagen V, tumour necrosis factor-a, interleukin-6 in liver cirrhosis after antiviral treatment.

BACKGROUND

To evaluate the therapeutic effects of entecavir combined with reduced glutathione on serum type III procollagen (PCIII), plasma procollagen V (IVC), Tumour Necrosis Factor-a (TNF-a), interleukin-6 (IL-6), and nutritional status in patients with hepatitis B complicated by alcoholic liver cirrhosis.

METHODS

This study included 92 patients with alcoholic liver cirrhosis and hepatitis B, treated between April 2022 and January 2024. Patients were randomised into two groups: group A received 0.5 mg of entecavir daily, and group B received 0.5 mg of entecavir daily plus 0.3 g of reduced glutathione 1-2 times per day for 2 months. Nutritional parameters, inflammatory markers, liver function, and malnutrition were compared between groups. Statistical analysis was performed using SPSS12.0, with independent t-tests for group comparisons and x2 tests for categorical data. A P-value <0.05 was considered statistically significant.

RESULTS

Group B showed a higher effective treatment rate (97.82%) compared to group A (76.08%). Malnutrition improved significantly more in group B. After treatment, group B exhibited more significant reductions in BMI, TSF, AMC, PA, Hb, ALB, TNF-a, CRP, IL-6, TBIL, AST, ALT, HA, PCIII, and IVC than group A.

CONCLUSIONS

Entecavir combined with reduced glutathione improves liver function and nutritional status and reduces inflammatory markers in patients with hepatitis B and alcoholic liver cirrhosis, demonstrating high safety and effectiveness.